Exact Sciences Co. (NASDAQ:EXAS) Stock Holdings Trimmed by Comerica Bank

Comerica Bank trimmed its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 75.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,803 shares of the medical research company's stock after selling 5,454 shares during the quarter. Comerica Bank's holdings in Exact Sciences were worth $101,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Soros Fund Management LLC boosted its position in Exact Sciences by 31.3% during the fourth quarter. Soros Fund Management LLC now owns 496,938 shares of the medical research company's stock worth $27,923,000 after acquiring an additional 118,348 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in shares of Exact Sciences by 384.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 21,708 shares of the medical research company's stock worth $1,220,000 after purchasing an additional 17,231 shares during the period. AQR Capital Management LLC lifted its stake in shares of Exact Sciences by 132.6% during the 4th quarter. AQR Capital Management LLC now owns 592,385 shares of the medical research company's stock worth $33,286,000 after purchasing an additional 337,727 shares during the period. Lido Advisors LLC boosted its holdings in shares of Exact Sciences by 351.5% during the fourth quarter. Lido Advisors LLC now owns 24,112 shares of the medical research company's stock worth $1,355,000 after purchasing an additional 18,772 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Exact Sciences by 30.0% in the fourth quarter. Northern Trust Corp now owns 1,147,271 shares of the medical research company's stock valued at $64,465,000 after purchasing an additional 264,430 shares during the period. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Evercore ISI increased their target price on Exact Sciences from $60.00 to $66.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Piper Sandler dropped their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Robert W. Baird raised their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Barclays upped their price target on shares of Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Finally, Scotiabank increased their price target on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Stock Down 0.7%

EXAS traded down $0.41 on Thursday, reaching $56.48. The company's stock had a trading volume of 2,680,348 shares, compared to its average volume of 2,589,969. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83. The business's 50 day moving average is $47.12 and its 200 day moving average is $52.06. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock has a market cap of $10.65 billion, a price-to-earnings ratio of -10.14 and a beta of 0.92.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.16. The company had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business's revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.60) EPS. As a group, research analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.